Evidence map›Paper›PMID 38568415›Full record

ArticleInflammation2024

RP105 Attenuates Ischemia/Reperfusion-Induced Oxidative Stress in the Myocardium via Activation of the Lyn/Syk/STAT3 Signaling Pathway.

Jian Yang, Yuhong Zhai, Cuiyuan Huang, Zujin Xiang, Haiyin Liu, Jingyi Wu, Yifan Huang, Li Liu, Wenqiang Li, Wei Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Components ofFrontiers in pharmacology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jian Yang *Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Yuhong Zhai *Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Cuiyuan Huang *Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Zujin XiangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Haiyin LiuDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Jingyi WuDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Yifan HuangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Li LiuDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Wenqiang LiDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Wei WangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China.
Jun YangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China. yangjun@ctgu.edu.cn.
Jing ZhangDepartment of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yiling Road 183, Yichang, 443000, Hubei, China. zhangjing@ctgu.edu.cn.
China Three Gorges University · CNSecond Hospital of Yichang · CN

Funding

Hubei Provincial Health Commission Project WJ2023M151Key Research and Development Program of Hubei Province 2022BCE001National Natural Science Foundation of China 82070372National Natural Science Foundation of China 82170418National Natural Science Foundation of China 82271618Natural Science Foundation of Hubei Province 2022CFA015Research Fund for Excellent Dissertation of China Three Gorges University 2021SSPY101Science and Technology Innovation Platform of Hubei Province 2022DCC014
6 · The paper itself

Abstract

Although our previous studies have established the crucial role of RP105 in myocardial ischemia/reperfusion injury (MI/RI), its involvement in regulating oxidative stress induced by MI/RI remains unclear. To investigate this, we conducted experiments using a rat model of ischemia/reperfusion (I/R) injury. Adenovirus carrying RP105 was injected apically at multiple points, and after 72 h, the left anterior descending coronary artery was ligated for 30 min followed by 2 h of reperfusion. In vitro experiments were performed on H9C2 cells, which were transfected with recombinant adenoviral vectors for 48 h, subjected to 4 h of hypoxia, and then reoxygenated for 2 h. We measured oxidative stress markers, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities, as well as malondialdehyde (MDA) concentration, using a microplate reader. The fluorescence intensity of reactive oxygen species (ROS) in myocardial tissue was measured using a DHE probe. We also investigated the upstream and downstream components of the signal transducer and activator of transcription 3 (STAT3). Upregulation of RP105 increased SOD and GSH-Px activities, reduced MDA concentration, and inhibited ROS production in response to I/R injury in vivo and hypoxia reoxygenation (H/R) stimulation in vitro. The overexpression of RP105 led to a decrease in the myocardial enzyme LDH in serum and cell culture supernatant, as well as a reduction in infarct size. Additionally, left ventricular fraction (LVEF) and fractional shortening (LVFS) were improved in the RP105 overexpression group compared to the control. Upregulation of RP105 promoted the expression of Lyn and Syk and further activated STAT phosphorylation, which was blocked by PP2 (a Lyn inhibitor). Our findings suggest that RP105 can inhibit MI/RI-induced oxidative stress by activating STAT3 via the Lyn/Syk signaling pathway.

Indexed as

Myocardial Reperfusion InjuryMyocardiumOxidative StressSignal TransductionSTAT3 Transcription FactorSyk KinaseAnimalsCell LineMaleRatsRats, Sprague-DawleyReactive Oxygen Speciessrc-Family Kinaseslyn protein-tyrosine kinaseReactive Oxygen Speciessrc-Family KinasesStat3 protein, ratSTAT3 Transcription FactorSyk Kinasehypoxia/reoxygenationmyocardial ischemia/reperfusion injuryoxidative stressRP105STAT3

Identifiers

PMID38568415
OpenAlexW4393867798

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.